C
Craig A. Smith
Researcher at Amgen
Publications - 18
Citations - 8441
Craig A. Smith is an academic researcher from Amgen. The author has contributed to research in topics: Receptor & Tumor necrosis factor alpha. The author has an hindex of 15, co-authored 18 publications receiving 8290 citations.
Papers
More filters
Journal ArticleDOI
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
Henning Walczak,Robert E. Miller,Kiley Ariail,Brian Gliniak,Thomas S. Griffith,Marek Kubin,Wilson Chin,Jon Jones,Anne Woodward,Tiep Le,Craig A. Smith,Pam J. Smolak,Raymond G. Goodwin,Charles Rauch,JoAnn C. L. Schuh,David H. Lynch +15 more
TL;DR: Recurrent treatments with LZ–huTRAIL actively suppressed growth of the TRAIL–sensitive human mammary adenocarcinoma cell line MDA–231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with Lz–hu TRAIL demonstrated clear areas of apoptotic necrosis within 9–12 hours of injection.
Journal ArticleDOI
Trail-r2: a novel apoptosis-mediating receptor for trail
Henning Walczak,Mariapia A. Degli-Esposti,Richard S. Johnson,Pam J. Smolak,Jennifer Y. Waugh,Norman Boiani,Martin Timour,Mary Gerhart,Kenneth A. Schooley,Craig A. Smith,Raymond G. Goodwin,Charles Rauch +11 more
TL;DR: The identification of a distinct receptor for TRAIL, TRAIL‐R2, by ligand‐based affinity purification and subsequent molecular cloning suggests an unexpected complexity to TRAIL biology, reminiscent of dual receptors for TNF, the canonical member of this family.
Journal ArticleDOI
Fas ligand mediates activation-induced cell death in human T lymphocytes.
Mark R. Alderson,T W Tough,T Davis-Smith,S Braddy,Ben A. Falk,K A Schooley,Raymond G. Goodwin,Craig A. Smith,Fred Ramsdell,David H. Lynch +9 more
TL;DR: In this article, a significant proportion of previously activated human T cells undergo apoptosis when triggered through the CD3/T cell receptor complex, a process termed activation-induced cell death (AICD).
Journal ArticleDOI
The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain
Mariapia A. Degli-Esposti,William C. Dougall,Pamela J. Smolak,Jennifer Y. Waugh,Craig A. Smith,Raymond G. Goodwin +5 more
TL;DR: Transient overexpression of TRAil-R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAilsR4 may be inhibition of TRAIL cytotoxicity.
Journal ArticleDOI
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
David A. Lawrence,Zahra Shahrokh,Scot A. Marsters,Kirsten Achilles,Danny Shih,Barbara Mounho,Kenneth J. Hillan,Klara Totpal,Laura DeForge,Peter Schow,Jeffrey Hooley,Steve Sherwood,Roger Pai,Susan Leung,Lolo Khan,Brian Gliniak,Jeanine L. Bussiere,Craig A. Smith,Stephen S. Strom,Sean K. Kelley,Judith A. Fox,Deborah Thomas,Avi Ashkenazi +22 more
TL;DR: These findings not only provide a novel insight into the pathogenesis of the transplant-related atherosclerosis, but also point to a new therapeutic strategy that involves targeting of homing, differentiation and proliferation of putative smooth-muscle progenitor cells derived from the recipient.